Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs

We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and r...

Descripción completa

Detalles Bibliográficos
Autores principales: Farooq, Hamzah Z., Cirillo, Daniela M., Hillemann, Doris, Wyllie, David, van der Werf, Marieke J., Ködmön, Csaba, Nikolayevskyy, Vlad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920658/
https://www.ncbi.nlm.nih.gov/pubmed/33622487
http://dx.doi.org/10.3201/eid2703.204418
_version_ 1783658321934286848
author Farooq, Hamzah Z.
Cirillo, Daniela M.
Hillemann, Doris
Wyllie, David
van der Werf, Marieke J.
Ködmön, Csaba
Nikolayevskyy, Vlad
author_facet Farooq, Hamzah Z.
Cirillo, Daniela M.
Hillemann, Doris
Wyllie, David
van der Werf, Marieke J.
Ködmön, Csaba
Nikolayevskyy, Vlad
author_sort Farooq, Hamzah Z.
collection PubMed
description We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited.
format Online
Article
Text
id pubmed-7920658
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-79206582021-03-04 Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs Farooq, Hamzah Z. Cirillo, Daniela M. Hillemann, Doris Wyllie, David van der Werf, Marieke J. Ködmön, Csaba Nikolayevskyy, Vlad Emerg Infect Dis Research Letter We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited. Centers for Disease Control and Prevention 2021-03 /pmc/articles/PMC7920658/ /pubmed/33622487 http://dx.doi.org/10.3201/eid2703.204418 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Farooq, Hamzah Z.
Cirillo, Daniela M.
Hillemann, Doris
Wyllie, David
van der Werf, Marieke J.
Ködmön, Csaba
Nikolayevskyy, Vlad
Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
title Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
title_full Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
title_fullStr Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
title_full_unstemmed Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
title_short Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
title_sort limited capability for testing mycobacterium tuberculosis for susceptibility to new drugs
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920658/
https://www.ncbi.nlm.nih.gov/pubmed/33622487
http://dx.doi.org/10.3201/eid2703.204418
work_keys_str_mv AT farooqhamzahz limitedcapabilityfortestingmycobacteriumtuberculosisforsusceptibilitytonewdrugs
AT cirillodanielam limitedcapabilityfortestingmycobacteriumtuberculosisforsusceptibilitytonewdrugs
AT hillemanndoris limitedcapabilityfortestingmycobacteriumtuberculosisforsusceptibilitytonewdrugs
AT wylliedavid limitedcapabilityfortestingmycobacteriumtuberculosisforsusceptibilitytonewdrugs
AT vanderwerfmariekej limitedcapabilityfortestingmycobacteriumtuberculosisforsusceptibilitytonewdrugs
AT kodmoncsaba limitedcapabilityfortestingmycobacteriumtuberculosisforsusceptibilitytonewdrugs
AT nikolayevskyyvlad limitedcapabilityfortestingmycobacteriumtuberculosisforsusceptibilitytonewdrugs

Ejemplares similares